HTFLHealthcareMid-Cap
Heartflow, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Heartflow, Inc. (HTFL), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are HTFL insiders buying or selling?
Heartflow, Inc. insiders reported 1 open-market buys ($1.1M) and 17 sells ($125.8M) across 18 Form 4 filings — a net selling position of $124.8M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 17, 2026)
Total Form 4 filings
18
SEC EDGAR
Insider filers
5
Insider buys (1)
$1.1M
Insider sells (17)
$125.8M
Insider sentiment
Net sellingNet insider flow of $124.8M in net selling.
Recent HTFL insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 9.2K | $25.72 | $237.1K |
| Jul 14, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $27.75 | $626.1K |
| Jun 26, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 38.9K | $35.00 | $1.4M |
| Jun 12, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $28.50 | $643.0K |
| May 20, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 9.2K | $28.34 | $261.3K |
| May 13, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $29.12 | $657.0K |
| May 1, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Sale | 2.0M | $29.45 | $58.9M |
| Apr 14, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $26.72 | $602.9K |
| Apr 3, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 64.5K | $24.64 | $1.6M |
| Mar 23, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 64.5K | $25.69 | $1.7M |
| Mar 20, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 9.7K | $25.00 | $243.1K |
| Mar 12, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 12.8K | $22.66 | $290.9K |
| Mar 7, 2026 | Julie A Cullivan | Director | Sale | 9.1K | $25.00 | $228.1K |
| Feb 18, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 65.2K | $24.49 | $1.6M |
| Feb 11, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $27.46 | $619.6K |
| Feb 7, 2026 | Julie A Cullivan | Director | Sale | 8.0K | $27.32 | $218.6K |
| Feb 6, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Sale | 2.0M | $28.05 | $56.1M |
| Dec 17, 2025 | Jeffrey C Lightcap | Director | Purchase | 40.0K | $26.34 | $1.1M |
Showing the 18 most recent of 18 Form 4 filings for Heartflow, Inc..
Most active HTFL insiders
- John C.M. Farquhar8 filings
- Campbell Rogers5 filings
- Bain Capital Life Sciences Investors, LLC2 filings
- Julie A Cullivan2 filings
- Jeffrey C Lightcap1 filing
Ask anything about HTFL insider activity
Use Trabud's AI agent to query Heartflow, Inc.'s Form 4 history in plain English — "Show me HTFL CEO purchases this year" or compare it against any other ticker.
Open the AI agentHTFL insider trading FAQ
Are Heartflow, Inc. insiders buying or selling?
Across 18 SEC Form 4 filings, Heartflow, Inc. (HTFL) insiders reported 1 open-market purchases totaling $1.1M and 17 sales totaling $125.8M. That is a net selling position of $124.8M.
How many insiders trade HTFL stock?
5 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Heartflow, Inc.. The most recent filing was accepted on Jul 17, 2026.
Where does Trabud get HTFL insider trading data?
All HTFL insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.